Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Recruiting
1,310 enrolled
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Recruiting
800 enrolled
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
63 enrolled
TMB-H
Phase 2 Recruiting
30 enrolled
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Phase 2 Recruiting
430 enrolled
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Phase 1 Recruiting
210 enrolled
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Recruiting
4,000 enrolled
ICE COMPRESS
Phase 3 Recruiting
777 enrolled
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
Phase 1 Recruiting
54 enrolled
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Phase 2 Recruiting
70 enrolled
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Phase 1 Recruiting
128 enrolled
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1/2 Recruiting
141 enrolled
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
168 enrolled
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Phase 1/2 Recruiting
223 enrolled
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
170 enrolled
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
200 enrolled
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 Recruiting
200 enrolled
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1/2 Recruiting
197 enrolled
CLINCH
Phase 1 Recruiting
156 enrolled
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Phase 1 Recruiting
308 enrolled
A Study of BG-C477 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
310 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Phase 1 Recruiting
63 enrolled
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Phase 1 Recruiting
105 enrolled
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
180 enrolled
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Phase 1 Recruiting
60 enrolled
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Recruiting
6,035 enrolled
ON-TRK
Recruiting
150 enrolled
NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Recruiting
100 enrolled
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Phase 1 Recruiting
190 enrolled
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Phase 1 Recruiting
31 enrolled
SNV1521 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
400 enrolled
Retinoblastoma Phase II Expanded Access Clinical Trial
Phase 2 Recruiting
30 enrolled
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
22 enrolled
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
Recruiting
20 enrolled
Study of TRX-920 for Patients With Advanced Solid Tumors
Phase 1 Recruiting
30 enrolled
ASCENT
Phase NA Recruiting
660 enrolled
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
Phase 1 Recruiting
72 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
Phase 1 Recruiting
45 enrolled
Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers
Phase NA Recruiting
50 enrolled
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
Phase 1 Recruiting
6 enrolled
Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person
Phase NA Recruiting
80 enrolled
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Phase 1 Recruiting
360 enrolled
A Study of MHB009C in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
200 enrolled
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Phase 1 Recruiting
149 enrolled
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting
1,000 enrolled
COMBINE-EGFR-1
Phase 1/2 Recruiting
933 enrolled